Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Intangibles: 2024-2025

Historic Intangibles for Day One Biopharmaceuticals (DAWN) over the last 2 years, with Sep 2025 value amounting to $18.8 million.

  • Day One Biopharmaceuticals' Intangibles rose 16.03% to $18.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.8 million, marking a year-over-year increase of 16.03%. This contributed to the annual value of $15.6 million for FY2024, which is N/A change from last year.
  • Latest data reveals that Day One Biopharmaceuticals reported Intangibles of $18.8 million as of Q3 2025, which was down 4.05% from $19.6 million recorded in Q2 2025.
  • Day One Biopharmaceuticals' 5-year Intangibles high stood at $20.4 million for Q1 2025, and its period low was $15.6 million during Q4 2024.
  • Over the past 2 years, Day One Biopharmaceuticals' median Intangibles value was $17.8 million (recorded in 2024), while the average stood at $17.9 million.
  • Data for Day One Biopharmaceuticals' Intangibles shows a peak YoY climbed of 16.71% (in 2025) over the last 5 years.
  • Quarterly analysis of 2 years shows Day One Biopharmaceuticals' Intangibles stood at $15.6 million in 2024, then rose by 16.03% to $18.8 million in 2025.
  • Its Intangibles was $18.8 million in Q3 2025, compared to $19.6 million in Q2 2025 and $20.4 million in Q1 2025.